pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›ASENAPINE
drug
save

ASENAPINE

updated 4mo ago
by SIGMAPHARM LABS LLC
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying ASENAPINE

  • phase3Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)completedn=277
  • phase3Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)completedn=481
  • phase33-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)completedn=489
  • phase2An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patients With a Psychotic Disorder (P07010)(COMPLETED)completedn=174
  • phase3Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)completedn=460
  • phase39 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)completedn=504
  • phase3Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)completedn=417
  • phase33-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)completedn=488
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Jul 25, 2033
~6.9 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (18)

  • Sep 22, 2033formulationUS 11813364
  • Sep 22, 2033formulationUS 11813364
  • Sep 22, 2033formulationUS 11813364
  • Jul 25, 2033formulationUS 10022445
  • Jul 25, 2033formulationUS 10022445
  • Jul 25, 2033formulationUS 10022445
  • Jul 25, 2033formulationUS 10583121
  • Jul 25, 2033formulationUS 10583121
  • Jul 25, 2033formulationUS 10583121
  • Jul 25, 2033formulationUS 10814002
  • Jul 25, 2033formulationUS 10814002
  • Jul 25, 2033formulationUS 10814002
  • Jul 25, 2033formulationUS 11123305
  • Jul 25, 2033formulationUS 11123305
  • Jul 25, 2033formulationUS 11123305
  • Jul 25, 2033formulationUS 9687474
  • Jul 25, 2033formulationUS 9687474
  • Jul 25, 2033formulationUS 9687474

News(0)

no news has mentioned this drug yet

brand
ASENAPINE
generic
ASENAPINE
Data sources
ClinicalTrials.gov
last refreshed 46m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?